A randomized, placebo-controlled clinical trial of hydrogen/oxygen inhalation for non-alcoholic fatty liver disease.
Geru Tao, Guangjie Zhang, Wei Chen, Chao Yang, Yazhuo Xue, Guohua Song, Shucun Qin · Journal of cellular and molecular medicine · 2022
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
H2HUBB TAKEAWAY
In 70 patients with percentages in parentheses, only 28.6% (2/7) participants had improved CT L/S in the placebo group after the trial, while 75% (6/8) participants in hydrogen/oxygen group showed alleviated hepatic steatosis. These findings add human evidence supporting molecular hydrogen's therapeutic potential for metabolic syndrome.
What the Findings Mean
H2HUBB reviewed how inhaled hydrogen gas affected the outcomes measured in 70 patients with percentages in parentheses. Only 28.6% (2/7) participants had improved CT L/S in the placebo group after the trial, while 75% (6/8) participants in hydrogen/oxygen group showed alleviated hepatic steatosis.
What the Researchers Studied
The researchers studied 70 patients with percentages in parentheses. The study used a randomized, placebo-controlled human clinical trial. The comparison condition was placebo.
What Effects Did Molecular Hydrogen Have?
Source-reported hydrogen concentration: 33% source-reported H₂ gas concentration; Source-reported hydrogen exposure: 33% source-reported H₂ gas concentration; reported treatment duration: 20 min. Only 28.6% (2/7) participants had improved CT L/S in the placebo group after the trial, while 75% (6/8) participants in hydrogen/oxygen group showed alleviated hepatic steatosis. The authors concluded that hydrogen/oxygen inhalation improved liver lipid level in moderate–severe cases based on ultrasound analysis. Molecular hydrogen (H₂ ), an anti-oxidative, anti-inflammatory biomedical agent is proved to exhibit therapeutic and preventive effect in various diseases. The purpose of this study was to investigate the effect of hydrogen/oxygen inhalation on NAFLD subjects and explore the mechanism from the perspective of hepatocyte autophagy.
Why These Findings Matter
These findings add human evidence supporting molecular hydrogen's therapeutic potential for metabolic syndrome and contribute to the growing body of molecular-hydrogen research.
How Strong Is This Evidence?
This is human clinical evidence from a randomized, placebo-controlled human clinical trial. H2HUBB interprets the findings in the context of the study design, sample, comparator, and measured outcomes rather than using one publication as a verdict on hydrogen therapy.
Technical Study Details
H2HUBB classifies this publication as human clinical study with human clinical evidence. The research population or model was 70 patients with percentages in parentheses. The reported sample size was 43. The study used a randomized, placebo-controlled human clinical trial. The hydrogen delivery method was inhaled hydrogen gas. The source-reported hydrogen concentration was 33% source-reported H₂ gas concentration. The reported treatment duration was 20 min.
Limitations and Safety
No separate limitations or safety findings were identified in the current-study source text available to H2HUBB.
Original Study and H2HUBB Research Context
H2HUBB presents this source-grounded research record as one contribution to the broader molecular-hydrogen evidence base.